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Background—MiR-137 dysregulation has been implicated in the etiology of schizophrenia, but 
its functional role remains to be determined.
Methods—Functional magnetic resonance imaging scans were acquired on 48 schizophrenia 
patients and 63 healthy volunteers (total sample size n=111 subjects), with similar mean age and 
sex distribution, while subjects performed a Sternberg Item Response Paradigm with memory 
loads of 1, 3, and 5 numbers. Dorsolateral prefrontal cortex (DLPFC) retrieval activation for the 
working memory load of 3 numbers, for which hyperactivation had been shown in schizophrenia 
patients compared with controls, was extracted. The genome-wide association study confirmed 
schizophrenia risk SNP rs1625579 (miR-137 locus) was genotyped (schizophrenia: GG n=0, GT 
n=9, TT n=39; healthy volunteers: GG=2, GT n=15, and TT n=46). Fisher's Exact Test examined 
the effect of diagnosis on rs1625579 allele frequency distribution (p=ns). Mixed model regression 
analyses examined the effects of diagnosis and genotype on working memory performance 
measures and DLPFC activation.
Results—Patients showed significantly higher left DLPFC retrieval activation on working 
memory load 3, lower working memory performance and longer response times compared with 
controls. There was no effect of genotype on working memory performance or response times in 
either group. However, individuals with the rs1625579 TT genotype had significantly higher left 
DLPFC activation than those with the GG/GT genotypes.
Conclusion—Our study suggests that the rs1625579 TT (miR-137 locus) schizophrenia risk 
genotype is associated with the schizophrenia risk phenotype DLPFC hyperactivation commonly 
considered a measure of brain inefficiency.
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Introduction
Aberrant dorsolateral prefrontal cortex (DLPFC) activation, as measured using functional 
magnetic resonance imaging (fMRI) during working memory processing, is a robust 
correlate of schizophrenia (1, 2). Consistent with DLPFC inefficiency - more activation for a 
similar level of performance - in schizophrenia (3), we have shown DLPFC hyper-activation 
during a working memory load of 3 items on the Sternberg Item Recognition Paradigm 
(SIRP) in schizophrenia patients compared with controls even when task performance is 
equivalent (4). We have identified several genetic polymorphisms that are associated with 
DLPFC activation in schizophrenia (5, 6) and subsequently identified several other putative 
schizophrenia risk genes as well as microRNAs based on a gene set enrichment analysis (7). 
MicroRNAs are short (<∼27 nucleotides) non-coding RNAs that regulate the expression 
levels of other genes (8) via mRNA cleavage or translation inhibition (9) and are 
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hypothesized to play a role in the genetic liability for schizophrenia (10, 11). The 
microRNAs identified in our prior study included miR-137 (7), which was recently 
suggested to play an etiological role in schizophrenia based on a very large genome-wide 
case-control association study of 51,695 individuals that found a genome-wide significance 
of p=1.6×10-11 for the rs1625579 SNP in linkage disequilibrium with the miR-137 primary 
transcript as well as significant associations with predicted miR-137 targets (12).
Apart from its observed role in cancer (13-15), miR-137 is shown to regulate neural stem 
cell proliferation and differentiation in mouse embryonic neural stem cells (NSC) (16), 
neurogenesis in mouse adult NSC (17) and neuronal maturation, including regulation of 
dendrite length, branch points, end points and spine density in mouse adult hippocampal 
neuroprogenitor-derived and mouse fetal hippocampus neurons (18). Decreased spine 
density has also been observed in the dorsolateral cortex of patients with schizophrenia 
compared with controls consistent with poor memory performance and suggests altered 
synaptic connectivity (19). Combined, these studies implicate miR-137-dysregulation in the 
etiology of schizophrenia and suggest that miR-137 may be involved in regulating DLPFC 
activation by affecting neural connectivity within the DLPFC resulting in abnormal 
(inefficient) neural transmission. The putative miR-137 rs1625579 schizophrenia risk SNP 
was not part of the Illumina Infinium HumanHap300 Bead Array used for genotyping in our 
prior work (5). In this study we genotyped the rs1625579 SNP in order to directly examine 
the association between the rs1625579 (miR-137 locus) schizophrenia risk alleles 
(genotypes) and SIRP 3 item probe DLPFC activation on the Sternberg Item Recognition 
Test; the SIRP contrast shown to best separate schizophrenia versus control DLPFC 
activation (4).
To date, four human studies have examined the functional role of the rs1625579 (miR-137) 
SNP in schizophrenia (20-23). Cummings and colleagues (2012) (23) recently found, in a 
sample of 399 schizophrenia, bipolar I disorder, and schizoaffective disorder patients and 
171 controls, that rs1625579 TT genotype was associated with poor working memory, 
episodic memory and attention. In contrast, Green and colleagues (2011) (12), who grouped 
schizophrenia patients into those with and without cognitive deficits, found that the 
rs1625579 SNP alone was not predictive of cognitive dysfunction severity or group status, 
but that the G-allele predicted cognitive dysfunction group status when negative symptoms 
were included in a multinomial regression analysis. The latter finding is hard to interpret 
given that the common rs1625579 T allele is associated with schizophrenia risk status.
An EEG study by Decoster and colleagues (21) found that the rs1625579 SNP T allele was 
associated with lower P300 amplitude. This finding is in the hypothesized direction in that 
P300 amplitude for common rs1625579 risk allele (T) appeared to be associated with lower 
P300 amplitude, a well-known quantitative endophenotype for schizophrenia (24). While the 
finding did not survive stringent Bonferroni correction, it nevertheless suggests a 
contribution of the rs1625579 (miR-137) SNP to the P300 deficit observed in schizophrenia 
that warrants further study.
A fMRI study by Whalley and colleagues (22) examined the effects of rs1625579 genotype 
on brain activation during a sentence completion task in individuals at genetic high-risk for 
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schizophrenia or bipolar disorder compared with healthy controls. They found a significant 
group by genotype interaction on left amygdala and pre/post central gyrus activation. 
Decomposition of the interaction effect showed that the interaction was due to higher 
activation in schizophrenia T allele homozygotes and lower activation in control T allele 
homozygotes compared with their respective G allele carriers during sentence completion 
versus baseline condition in the left amygdala and pre/post central gyrus. They also found 
lower right posterior medial frontal gryus activation in rs1625579 T allele homozygotes 
compared with G allele carriers for a contrast sensitive to the difficulty of sentence 
completion irrespective of group status. These findings suggest that miR-137 gene 
regulation may affect brain physiology as measured with fMRI.
In this first working memory study examining the effects of rs1625579 genotypes on BOLD 
activation in schizophrenia, we hypothesize (1) lower SIRP load 3 working memory 
performance and longer response times in schizophrenia patients compared with healthy 
volunteers and (2) higher left DLPFC SIRP probe 3 activation in schizophrenia patients 
compared with healthy volunteers, consistent with findings from our previous report (4). 
Looking at specific effects of the rs1625579 (miR-137) SNP, our explicit directional 
hypothesis is (3) higher left DLPFC SIRP probe 3 activation for the rs1625579 T 
(schizophrenia risk) allele compared with G (non-risk) allele carriers (TT > GT > GG 
genotypes) consistent with higher neural inefficiency in the schizophrenia rs1625579 risk 
allele carriers. Given the low frequency of the rare GG genotype we collapsed across the GG 
and GT genotypes in the analyses and compared GG/GT with TT genotypes. We 
specifically focus on DLPFC retrieval activation on SIRP load 3 because it showed the 
strongest hyperactivation in patients with schizophrenia compared with controls even when 
behavioral performance was matched between the groups (4). We also explored whether the 
hypothesized genetic effect added to or interacted with diagnosis.
Methods and Materials
Participants
Forty-eight patients with schizophrenia (mean age±standard deviation (SD) = 37.0±10.7, 35 
males) and 63 healthy volunteers (mean age±SD = 37.6±12.4, 39 males) with similar mean 
age, sex, handedness and race distributions, recruited from 9 sites part of the Function 
Biomedical Informatics Network Phase 2 study on multi-center functional imaging, 
participated in the study (Table 1). Study participants were between the ages of 18-70, had 
regular hearing levels (<25-db loss in either ear), had sufficient eyesight to see the task 
stimuli, were fluent in English and able to perform the cognitive tasks in the study. Inclusion 
criteria for the patients were a schizophrenia diagnosis based on the Structured Clinical 
Interview for DSM-IV-TR Axis I Disorders (SCID-I/P) (25). All patients were clinically 
stable on antipsychotic medication for at least two months. Schizophrenia patients and 
healthy volunteers with a history of major medical illness, a previous head injury or 
prolonged unconsciousness, substance and/or alcohol dependence, current migraine 
treatments, contraindications for MRI, and/or an IQ less than 75 were excluded. Patients 
with schizophreniform disorder or significant extrapyramidal symptoms / tardive dyskinesia 
and healthy volunteers with a current or past history of major neurological or psychiatric 
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illness (SCID-I/NP) (26) or with a first-degree relative with an Axis-I psychotic disorder 
diagnosis were also excluded.
Both patients and controls were assessed with demographic and other socioeconomic 
questionnaires, the Edinburgh Handedness Questionnaire (27), the Fagerstrom Test for 
Nicotine Dependence (28) and the North American Adult Reading Test (29). Patients were 
assessed with the Scales for the Assessment of Positive (30) and Negative (31) Symptoms, 
Schedule for the Deficit Syndrome (32), Calgary Depression Scale (33), InterSePT Scale for 
Suicidal Thinking (34), Abnormal Involuntary Movement Scale (35), Barnes Akathisia 
Rating Scale (36), and the Simpson-Angus Scale (37). Ratings were standardized across 
sites through cross-site group training sessions with experienced clinical raters and by rating 
videotapes from several patients for comparisons with expert assessments.
Written informed consent, including permission to share de-identified data between the 
centers and with the wider research community, approved by University of California Irvine, 
California Los Angeles, New Mexico, Iowa, Minnesota, North Carolina as well as Brigham 
and Women's Hospital, Massachusetts General Hospital, Yale and Duke University 
Institutional Review Boards, was obtained from all study participants.
Genotyping
We genotyped the rs1625579 SNP reported in the recent GWAS study (12). Three 
intergenic Infinium HumanHap300 Bead Array SNPs [rs1938570 (LD=0.828), rs1702292 
(LD=0.806), and rs4378243 (LD=0.8)] are in > 80% LD with rs1625579, but are at greater 
distance to miR-137. Genotyping of rs1625579 was performed by real-time PCR using 
TaqMan® probes and primers (Applied Biosystems). We performed PCRs on 10ng of 
genomic DNA in a 5μL final volume using the TaqMan® Genotyping Master Mix and 
TaqMan® SNP genotyping assay on a 7900 HT real time sequence detector (Applied 
Biosystems). The TaqMan assay was previously validated by Sanger sequencing with 100% 
concordance on 10 random samples.
Sternberg Item Recognition Paradigm
Participants performed the Sternberg Item Recognition Paradigm (SIRP), a working memory 
paradigm comprised of encoding, delay, and recognition phases (Figure 1). During encoding 
participants memorized 1, 3, or 5 red digits that were visually presented for 6 seconds. 
Following a 2.7s delay, 14 green single probe digits were presented serially (50% targets) 
and participants indicated, via button-box presses, whether a probe was a target or foil 
(member or non-member of the memorized set, respectively). Probe digits were presented 
for 1.1s followed by a jittered delay (0.6s-2.486s). After each task block (Load 1, 3, or 5) a 
jittered duration (mean=12s, range: 4-20s) screen with a flickering cross was presented. 
Each of the 3 working memory loads was presented twice in pseudo-random order within a 
run and each participant performed 3 runs. Stimulus presentation and response collection 
was performed with E-Prime (Psychology Software Tools, Inc.) and participants performed 
at least one practice run independently prior to the scan to ensure that that they were able to 
achieve > 75% accuracy on the task. To sustain subject motivation throughout the imaging 
session, participants were able to earn 5 cents for each correct task response. Mean accuracy 
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and mean response times were calculated for each of the working memory loads (for 
additional task paradigm details see (4)).
Image Acquisition
Imaging data were acquired at nine imaging centers (4) and included: a localizer for 
identification of the AC-PC axis, a high-resolution sagittal T1-weighted scan (GE: FSPGR; 
Siemens: MP-RAGE, with FOV=24cm, 1.2-1.5mm slice thickness, 160-170 slices), a T2-
weighted scan to set slice prescription for the functional imaging scans (FOV=22cm, 
matrix=256×192, 27 slices [thickness/gap=4mm/1mm]), b0 field maps on the Siemens 
scanners, and T2*-weighted gradient echo EPI scans (FOV=22cm, TR/TE=2s/30ms, flip 
angle=90°, matrix=64×64, and 27 AC-PC aligned slices [thickness/gap=4mm/1mm]). 
Participants were required to have a normal night of sleep and no more than one alcoholic 
drink the night prior to the scan. Subjects refrained from caffeinated beverages two hours 
and smoking 40 minutes before the scan.
Image Analysis
We obtained DLPFC activation data from one of our previous studies (4). Detailed image 
analysis procedures are provided in Potkin et al. (2009) (4) and detailed multi-center fMRI 
quality assurance procedures have been reported on in Glover et al. (2012). Briefly, blind to 
group errors in the imaging data were identified via image meta-data files, NIfTI image 
headers, by visual inspection of the raw EPI data (e.g., poor fat suppression, poor slice 
prescription), and by AFNI's 3dToutcout (38) tool (runs with more than 34 out of 177 
volumes with outlier spikes were removed from the analyses) (4). EPI data were corrected 
for head movement using FMRIB Software Library (FSL(39))'s MCFLIRT by aligning all 
EPI volumes to the middle volume of each run, FSL's PRELUDE and FUGE were used to 
B0 correct images, slice-time correction was performed and images were smoothed to 8mm 
FWHM (40).
First-level statistical analyses were carried out for each run using the general linear model, 
predicting time series functional imaging data with encoding and recognition epochs 
convolved with a double gamma hemodynamic response function. Temporal derivatives 
were included in the model to allow for a better fit of the data by accounting for temporal 
variation. Statistical contrasts included encoding and recognition epochs versus fixation 
baseline as well as between-load contrasts. First-level statistical images were registered to 
the MNI-152 standard space using a 12-parameter affine transformation (41) and second-
level fixed effects analyses combined the three runs from each subject. Blind to group base 
images with obvious structural flaws or a Jaccard (overlap) index of the base image to the 
MNI-152 atlas larger than 1.5 interquartile range above the 75th percentile of the remaining 
values, and second-level statistical maps with clear evidence of excessive noise (n=6) were 
excluded from further analyses. Third-level random effects analyses were performed to 
create contrast maps for patients and controls separately (p<0.05, FDR correction).
The left DLPFC region of interest (ROI) used in this study included the union of all gray 
matter voxels that showed significant probe-associated increases with working memory load 
(p<0.05, based on FDR correction) in either the SZ or HV group analysis within Brodmann 
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areas 9 and 46 of the WFU PickAtlas (42, 43). This combined structural-functional ROI 
selection method was chosen to confine the extraction of percent signal change to the 
DLPFC while allowing for group differences in activation patterns across subregions of the 
DLPFC and reducing the likelihood of washing out our hypothesized group differences due 
to signal averaging over a large region. DLPFC percent signal change was extracted from 
the second level contrast of parameter estimates (copes) images.
Statistical Analyses
Given the low frequency of the rs16255579 GG genotype, the distribution of rs1625579 
genotypes across diagnoses was examined using the Fisher's Exact Test (Statistical Analysis 
Systems [SAS 9.2], Proc Freq). The frequency distribution of rs1625579 genotypes did not 
differ between patients and controls (Table 1). The rs1625579 genotype frequency 
distributions for both patients and controls were in Hardy-Weinberg Equilibrium. Given that 
only two controls had the rare GG genotype, GG and GT genotypes were collapsed in all 
subsequent analyses. Group (patient/control) and genotype (GG+GT/TT) effects on left 
DLPFC SIRP load 3 probe activation were examined using four univariate mixed model 
regression analyses (SAS 9.2, Proc Mixed) in which left DLPFC probe 3 activation was 
predicted either with: 1) diagnosis (patient/control), to confirm DLPFC hyper-activation in 
patients compared with controls; 2) genotype (GG+GT/TT), to test the hypothesis that the 
rs1625579 T allele is associated with DLPFC hyper-activation, 3) diagnosis and genotype, 
to examine whether group or genotype add in predicting DLPFC activation, and 4) 
diagnosis, genotype, and the diagnosis × genotype interaction, to examine whether group 
and genotype interact in predicting DLPFC activation ([SZ-TT versus HV-TT] > [SZ-
GG/GT versus HV-GG/GT]). All analyses included site, sex, and age as covariates and used 
planned one-tailed contrast analyses to test the specified directional hypotheses for 
diagnosis, genotype, and diagnosis × genotype effects. Analyses using similar models were 
performed to examine diagnosis and possible rs1625579 genotype effects on SIRP load 3 
working memory performance and response times. Even though a prior analyses showed no 
evidence of sample stratification (5), in the current analysis we controlled for the possible 
confound of rs1625579 allele frequency differences between ethnicities by re-analysis of the 
data in a CEU-only sample, identified based on a HAPMAP3-based multi-dimensional 
scaling and cluster analysis (http://pngu.mgh.harvard.edu/purcell/plink; (44)). In addition to 
our hypothesis-driven DLPFC region of interest analysis, we performed an exploratory 
analysis in image space examining the effect of rs1625579 genotype on 3 item SIRP probe 
activation (z>2.3, p<0.05) with a mixed effects analysis using FSL(39)'s FLAME controlling 
for age, sex, site, and diagnosis.
Results
Mixed model regression analyses confirmed left DLPFC hyper-activation for SIRP load 3 
probes in SZ patients compared with health volunteers (t100=1.91, p=0.03). Individuals 
carrying the common miR-137 schizophrenia risk genotype (rs1625579 TT) showed hyper-
activation compared with those carrying the less frequent GG/GT genotype (t100=2.17, 
p=0.02) (Figure 2). The analysis of additive effects of genotype and diagnoses showed 
significant effects of genotype (TT > GG/GT; t99=1.99, p=0.03) as well as diagnosis (SZ > 
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HV; t99=1.77, p<0.05) on left DLPFC activation. The analysis of interaction effects of 
genotype and diagnosis did not show a significant interaction effect (t98=0.35, p=0.36) on 
left DLPFC activation, while the main effects for diagnosis and genotype remained similar. 
Analysis of the CEU-only sample showed similar, but more highly significant findings for 
diagnosis (t65=3.89, p=0.02) and genotype (t65=4.20, p=0.01) and no significant interaction. 
Behavioral data analysis confirmed the significantly lower working memory performance 
(t96=-3.5, p=0.0007) and longer response times (t76=40.95, p=0.0005) on SIRP load 3 in 
schizophrenia patients (LSMean±StdErr=89%±1.3; 951ms±27) compared with healthy 
volunteers (94%±1.0; 837ms±20) previously observed (4), but working memory 
performance and response times were similar for rs1625579 genotypes: 92%±0.8 versus 
92%±1.4 and 869ms±17 versus 918ms±29 for TT and GG/GT genotypes, respectively. 
Exploratory whole brain comparisons found two significant clusters in which individuals 
with rs1625579 TT genotypes showed higher activations compared with rs1625579 GG/TG 
genotypes (Figure 3). There were no significant rs1625579 GG/TG > TT clusters. While the 
DLPFC activations were not part of the significant clusters, there was a peak activation in 
the left DLPFC (z=2.67, P<0.004, uncorrected; see Figure 3).
Discussion
The main finding of our study is that the rs1625579 TT (miR-137) schizophrenia risk 
genotype is associated with left DLPFC hyperactivation compared with the combined 
GG/GT genotype irrespective of diagnosis. Given equivalent working memory performance 
between rs1625579 TT and GG/GT carriers, we interpret the observed DLPFC 
hyperactivation in individuals with the rs1625579 TT genotype compared with those with 
the GG/GT genotypes as being consistent with neural inefficiency in rs1625579 
schizophrenia risk allele carriers; similar to DLPFC inefficiency observed in patients with 
schizophrenia (3, 4). To our knowledge, this is the first report of a link between the 
rs1625579 SNP (miR-137) and working memory associated brain activation as measured 
with fMRI.
The biology underlying the observed miR-137 TT genotype associated neural inefficiency is 
as of yet unknown though studies of miR-137 expression in mice have shown that miR-137 
regulates neural stem cell proliferation and differentiation (16), neurogenesis (17), and 
neuronal maturation (18). Together with evidence that miR-137 is highly expressed in the 
rat neuron synaptosome compared to the cytosome (45) and evidence of reduced spine 
density in DLPFC cortical pyramidal neurons in schizophrenia, these findings suggest that 
miR-137 may be involved in the development of dysfunctional (neural, synaptic) 
connectivity within the DLPFC (19) as well as possibly between brain regions (46, 47).
To date, no human post-mortem studies have shown aberrant expression of miR-137 in 
brains of adult patients with schizophrenia compared with controls; for review see (48). 
However, recent in-vitro data that 5 schizophrenia candidate genes are regulated by miR-137 
(49, 50) strongly suggests a role for miR-137 in schizophrenia. Moreover, it is possible that 
other mechanisms like differential expression miR-137 across the lifespan or epigenetic 
mechanisms regulating miR-137 target genes may account for the lack of observed effects in 
published postmortem work. In fact, miR-137 does not function in isolation but is indirectly 
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regulated by miR-132 (17) whose expression has been found to differ between patients and 
controls in several studies (51) and may also be influenced by more general perturbations in 
the microRNA biogenesis pathway (48).
With regard to the functional phenotype associated with the miR-137 risk SNP in living 
humans, there is some convincing evidence of an impact of miR-137 on cognition (23, 45), 
some evidence of an impact on the P300 ERP component (21) and on the fMRI-based 
BOLD signal (22), including that reported in the current study. Of interest is also that some 
cases diagnosed with autism spectrum disorder with hemizygous deletions on chromosome 
1p21.3 have been reported (52). Autism has established clinical and genetic overlap with 
schizophrenia (53-55) and the possible involvement of miR-137 in chromosome 1p21.3 
deletion syndrome was recently investigated (45).
In sum, there are several lines of converging evidence that miR-137 may play a role in 
schizophrenia. The GWAS finding by Ripke and colleagues (12) in conjunction with the 
GSEA finding by Potkin and colleagues (7), miR-137 involvement in developmental brain 
processes (16-18, 45), the confirmed regulation of schizophrenia candidate genes by 
miR-137 (49, 50), some recent observations of rs1625579 associations with cognition (23, 
45), EEG (21), and fMRI (22) measures as well as the therapeutic promise of microRNA 
related treatments provide impetus for future studies of the role of miR-137 in 
schizophrenia. The findings from this paper suggest that miR-137 may regulate neural 
efficiency shown to be abnormal in schizophrenia.
Our findings lend further support to the use of fMRI-based physiological activations to 
understand the brain effects of schizophrenia liability genes (56) including those that 
regulate other genes (e.g, miRNAs). They encourage further investigation of miR-137 
microstructure, expression of miRNA in different cell types and compartments, its 
interactions with other non-coding elements [e.g., miR-132] and its target genes (49, 50). It 
must be noted that DLPFC inefficiency is influenced by other gene variations, including 
ones that affect neurotransmitter levels such as DAOA and COMT (57) and spine density 
such as DISC1 (58), corroborating the interpretation that genes contributing to altered 
synaptic connectivity may influence DLPFC inefficiency.
Strengths of the study are 1) that it used a well-established Sternberg item response 
functional imaging paradigm that shows robust hyperactivation in schizophrenia patients 
compared with controls (for retrieval at load 3) when using data collected from multiple 
scanners even when behavioral performance is matched between the groups (4), 2) that it 
examined a gene identified by a very large GWAS study with independent sample 
replication (12) as well as implicated by an independent group (7), 3) that activation 
differences were observed between genotypes despite similar SIRP load 3 working memory 
performance and response times, 4) that the rs1625579 genotypes were based on a validated 
genotyping assay, which is considered less ambiguous than based on imputation (59), 5) that 
the strength of the findings increased in a more homogeneous, CEU-only sample which 
controls for possible stratification confounds, and 6) that a voxelwise comparison, while not 
cluster-level significant, showed a peak activation (rs1625579 TT > GG/TG) in the left 
DLPFC. Some limitations must also be noted. The sample size is relatively small for a 
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genetic study without a replication cohort. However, concerns about type I error are 
minimized given that 1) the study examines the functional role of the rs1625579 risk SNP 
which was identified as a schizophrenia risk allele based on a GWA study with a cohort of 
51,695 individuals that included a replication sample, 2) the significant rs1625579 risk SNP 
effects on DLPFC activation were in the a priori predicted direction (DLPFC 
hyperactivation in patients with schizophrenia as well as in individuals with the 
schizophrenia risk allele (T)), and 3) the effects were in the same direction for both patients 
and controls. The G allele is rare and our sample included only two controls with the GG 
genotype and therefore did not allow for a more parametric analysis of the genotype effect 
(TT>GT>GG). The rs1625579 SNP maps about 9kb from the pre-miR137 sequence within 
an intron of the MIR137HG locus telomeric to the pre-miR137 sequence that maps within 
the 3rd exon of the MIR137HG. The high LD of the region extends to include the gene 
DPYD (60). A clump-LD analysis cannot exclude that rs1625579 may map to DPYD which 
is also a predicted miR-137 target (61).
MiR-137 was previously implicated in a gene set enrichment analysis (7), a SNP 
(rs1625579) recently showed the strongest effect in a GWA study with a discovery sample 
of 21,856 and a replication sample of 29,839 independent individuals (12), and shows an 
association with a schizophrenia phenotype that has been well-characterized in a large 
functional imaging study (4). This phenotype that has been shown to be highly heritable (62) 
in a region shown to be highly correlated with genetic liability for schizophrenia (63, 64) 
lending significant weight to the finding and encouraging further exploration of the 
functional role of miR-137 in schizophrenia etiology.
Our study suggests that the putative miR-137 locus rs1627759 TT schizophrenia risk 
genotype (12) is associated with DLPFC hyper-activation; a known schizophrenia risk 
phenotype and a measure of brain inefficiency. These findings suggest that the functional 
implications of miR-137 gene-regulation are measurable with functional magnetic resonance 
imaging even at relatively modest sample sizes and that the miR-137 gene regulatory 
network merits further investigation with regard to its etiological role in schizophrenia.
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In This Issue Statement
The SNP rs1625579 (miR-137 locus) confers risk for schizophrenia based on a recent 
genome wide association study including 51,695 individuals, but its functional role 
remains to be determined. This study examined the association between rs1625579 
genotypes and dorsolateral prefrontal cortex activation during working memory. The 
study found that the schizophrenia risk genotype rs1625579 TT is associated with the 
schizophrenia risk phenotype DLPFC hyperactivation commonly considered a measure 
of brain inefficiency.
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Figure 1. Sternberg Item Response Paradigm
The Sternberg Item Response Paradigm (SIRP) is a working memory paradigm in which 
participants study 1, 3, or 5 digits. After a delay they are presented with 14 probe digits. 
Participants are asked to indicate via button press whether or not the probe digits were part 
of the study set.
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Figure 2. miR-137 rs1625579 TT Genotype associated with DLPFC Hyper-activation during 
Working Memory
Individuals with rs1625579 TT genotypes show higher left dorsolateral prefrontal cortex 
probe activation on SIRP working memory load 3 than individuals with the rs1625579 GT 
or GG genotypes. Schizophrenia patients (SZ) show higher dorsolateral prefrontal cortex 
probe activation on working memory load 3 than healthy volunteers (HV).
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Exploratory Whole Brain Analysis.
Cluster Index Z x y z FSL Harvard-Oxford Cortical Atlas Label
Blue 3.8 -22 -68 8 Left Intracalcarine Cortex
Blue 3.84 -18 -48 -2 Left Lingual Gyrus
Blue 3.98 20 72 10 Left Intracalcarine Cortex
Blue 4.25 -12 -40 -4
Left Parahippocampal Gyrus, posterior division; extending into the 
Left Lingual Gyrus
Green 3.45 -46 -14 18 Left Central Opercular Cortex
Green 3.46 -50 -24 2 Left Planum Temporale
Green 3.72 -48 -22 6 Left Heschl's Gyrus
Green 4.11 -6 -22 28 Left Cingulate Gyrus, posterior division
Peak DLPFC Voxel 2.67 -36 30 24 Left Middle Frontal Gyrus (p<0.004, uncorrected)
Exploratory whole brain comparison of rs1625579 TT versus GG/TG genotypes showed two 
significant clusters (z=2.3, p<0.05), which included peak activations in the Left Cingulate 
Gyrus - posterior division, Left Heschl's Gyrus extending into the Left Planum Temporale, 
the left Central Opercular Cortex, the Left Parahippocampal Gyrus – posterior division, 
extending in the Left Lingual Gyrus and Left Intracalcarine Cortex; Left Figure). 
Exploratory examination beyond the significant clusters, for the rs1625579 TT > rs1625579 
GG/TG genotype contrast at z=2.67, p<0.004 (uncorrected) showed significant voxels in the 
Left Middle Frontal Gyrus activation (Right Figure).
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